AMGEN CONFIRMS COURT FILING
AMGEN CONFIRMS COURT FILING THOUSAND OAKS, Calif., Jan. 17 /PRNewswire/ -- Amgen Inc.
(NASDAQ National Market System: AMGN) today confirmed that the Company filed a complaint for Declaratory Judgment of Patent Non-Infringement, Invalidity, and Unenforceability against Chugai Pharmaceutical, Co., Ltd. (Chugai) in respect to certain U.S. patents issued to Chugai relating to granulocyte colony-stimulating factor (G-CSF). In addition, the complaint alleges violation of 18 U.S.C., sections 1961 et. seq., and common law fraud. The complaint was filed today in the U.S. District Court for the District of Columbia.
Amgen is seeking a declaratory judgment by the U.S. District Court that certain Chugai patents are not infringed by Amgen and are invalid and unenforceable. Amgen is an international pharmaceutical company that develops, manufactures and markets human therapeutics based on advanced cellular and molecular biology. -0- 1/17/92 /CONTACT: Sarah H. Crampton, 805-499-5725, ext 3250 (office) 805-499-4727 (home), or Kimberly L. Dorsey, 805-499-5725, ext 4367 (office) 805-373-6161 (home), both of Amgen/ (AMGN) CO: Amgen Inc. ST: California IN: MTC SU:
CH -- LA020 -- 1172 01/17/92 17:26 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 17, 1992|
|Previous Article:||McDONNELL DOUGLAS RECEIVES A $14.7 MILLION CONTRACT FOR RECERTIFICATIONS OF U.S. NAVY TOMAHAWK SEA-LAUNCHED CRUISE MISSILES|
|Next Article:||THE TORONTO STOCK EXCHANGE MARKET CLOSING|